Nika Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Nika Pharmaceuticals has been growing earnings at an average annual rate of 4.9%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 184.7% per year.
Key information
4.9%
Earnings growth rate
12.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 184.7% |
| Return on equity | n/a |
| Net Margin | -84,283.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Nika Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | 0 | 0 | 0 |
| 31 Mar 24 | 0 | 0 | 0 | 0 |
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | -3 | 0 | 3 |
| 31 Dec 22 | 0 | -3 | 0 | 3 |
| 30 Sep 22 | 0 | -3 | 0 | 3 |
| 30 Jun 22 | 0 | -3 | 0 | 3 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 30 Sep 21 | 0 | 0 | 0 | 0 |
Quality Earnings: NIKA is currently unprofitable.
Growing Profit Margin: NIKA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NIKA is unprofitable, but has reduced losses over the past 5 years at a rate of 4.9% per year.
Accelerating Growth: Unable to compare NIKA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NIKA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: NIKA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.